COVID-19

  1. Supply Chain Agility: Did You Have It Last Year? What About Now? 2/24/2021

    Who wants to revisit the challenges of 2020? Perhaps we should – and focus that retrospection on supply chain agility. Did you have it then? Do you now? In an as-it’s-happening whitepaper based on a survey and interviews, IDC chronicled the thoughts of supply chain executives during COVID disruptions.

  2. Novartis Manufacturing For Pfizer: It's Not Unusual 2/4/2021

    Breaking news: This isn’t quite the breaking news it’s been made out to be. It sure is good news. And the attention it’s getting is deserved and understandable. However, to be clear: Big Pharma manufacturing for other pharma is not uncommon.

  3. Nationalism And Voting For U.S.-Based Supply Chains 1/27/2021

    One election is over, but the results are still coming in on a second. Some self-examination is in order on how our political perceptions may influence our supply-chain decisions.

  4. What Role Will India Play In The Global COVID-19 Vaccine Narrative? 1/27/2021

    While most Americans are focused on the incredible success of the COVID-19 vaccines developed and produced by Pfizer and Moderna under the $24 billion Operation Warp Speed, there is under-reported news from India that bears a closer look.

  5. New Year's Resolution: Teach Industry About COVID-19 Supply Chain Challenges 1/1/2021

    When vaccines have been administered and COVID-19 is at bay, hopefully the vaccine makers and their partners will provide the entire drug development and manufacturing industry with details about the challenges they encountered in their supply chains.

  6. Remembering The Year We'd Rather Forget 12/19/2020

    We verified through a dismaying pandemic, outsourcing drug development and manufacturing is sustainable. But this annus horribilis also laid bare supply-chain vulnerabilities. Here’s the best and worst of your 2020.

  7. COVID-19 And Beyond: Perspectives From A Regulatory Affairs Professional 12/7/2020

    COVID-19 has significantly impacted our daily life, work, and productivity and has manifested social, economic, and cultural issues.

  8. Contingency Planning For Quality In The Cell And Gene Sector Due To COVID-19 12/7/2020

    Maintaining clinical trials during the COVID-19 pandemic has presented quite a challenge for those companies exploring novel therapies.

  9. Meet Your New “Person”-In-Plant: iPad On IV, Ph.D. 12/1/2020

    Joseph Graskemper of Translate Bio was recently involved in a process to create a V-PIP [virtual person-in-plant] at his CDMO. Turns out to be something that should carry on post-COVID-19, and prompt readers and your service providers to some ingenuity of your own.

  10. Regenerative Medicine Research & COVID-19 11/30/2020

    Clinical research has been severely impacted by the COVID-19 shutdown.